<div style="text-align:justify;"> <span style="font-family:Verdana;">Type 2 diabetes mellitus is a growing health problem, characterized by insulin resistance progressing to beta cell d...<div style="text-align:justify;"> <span style="font-family:Verdana;">Type 2 diabetes mellitus is a growing health problem, characterized by insulin resistance progressing to beta cell dysfunction and insulin deficiency, most of these patients will need intensification of treatment and initiation of insulin to delay or prevent diabetic complications. Glycemic control is the most important aspect of management, and in reducing morbidity and mortality of the diseases. Control of plasma glucose in patients with diabetes can be assessed by HbA1c, FPG, PPG, but still HbA1c% remains the gold standard for assessment of glycemic control and follow up of diabetic patients. The aim of this study is to assess HbA1c% in patients on oral anti-diabetic drugs, with poor glycemic control before and after adding basal insulin, with titration of the dose of insulin depending on fasting blood sugar. 82 patients with uncontrolled type 2 diabetes (43.9% male, 56.1% female), with HbA1c more than 9%, on two types of oral diabetic medication or more, were started on basal insulin (glargine, lantus) and followed for three to six months. Overall 82 patients with type 2 diabetes mellitus were included in the study. The mean age of the study population was 58.4 years, the mean duration of the disease range was 13.4 years. All patients with HbA1c more than 9%, without organ failure, were included in the study. The mean HbA1c overall had decreased from mean of 11.15% before starting basal insulin to the mean of 8.43% within 3 to 6 month, after initiating basal insulin, this difference was significant at p < 0.001. There was no adverse effect on this medication in any of the study group. The addition of basal insulin to oral anti-diabetic medication in uncontrolled insulin-na<span style="color:#4F4F4F;font-family:"font-size:14px;white-space:normal;background-color:#F7F7F7;">ï</span>ve type 2 diabetic patients resulted in significant improvement of glycemic control, with improved HbA1c level, without adverse effects.</span> </div>展开更多
糖基化血红蛋白（glycosylated hemoglobin）是伊朗科学家Ranbar等应用琼脂糖凝胶电泳分析率先从糖尿病患者血液中发现的一种血红蛋白组分，且研究表明，是血液葡萄糖对HbA的非遗传修饰产生了糖化血红蛋白A1c（haemoglobinA1c,HbA1c）[1...糖基化血红蛋白（glycosylated hemoglobin）是伊朗科学家Ranbar等应用琼脂糖凝胶电泳分析率先从糖尿病患者血液中发现的一种血红蛋白组分，且研究表明，是血液葡萄糖对HbA的非遗传修饰产生了糖化血红蛋白A1c（haemoglobinA1c,HbA1c）[1,2]。从此，他们与糖尿病的相关性得到确认，这一发现奠定了HbA1c检测用于糖尿病的初筛和诊断的基础。美国糖尿病控制及并发症试验（Diabetes Control and Complications Trial,DCCT）和英国前瞻性糖尿病研究（UK Prospeetive Diabetes Study,UKPDS）历时多年的糖尿病流行病学研究表明糖尿病患者通过治疗，控制平均血糖水平和HbA1c，能够有效地得到治疗，显著降低视网膜病变、肾脏疾病以及神经病变等并发症的发生及其严重程度。展开更多
文摘<div style="text-align:justify;"> <span style="font-family:Verdana;">Type 2 diabetes mellitus is a growing health problem, characterized by insulin resistance progressing to beta cell dysfunction and insulin deficiency, most of these patients will need intensification of treatment and initiation of insulin to delay or prevent diabetic complications. Glycemic control is the most important aspect of management, and in reducing morbidity and mortality of the diseases. Control of plasma glucose in patients with diabetes can be assessed by HbA1c, FPG, PPG, but still HbA1c% remains the gold standard for assessment of glycemic control and follow up of diabetic patients. The aim of this study is to assess HbA1c% in patients on oral anti-diabetic drugs, with poor glycemic control before and after adding basal insulin, with titration of the dose of insulin depending on fasting blood sugar. 82 patients with uncontrolled type 2 diabetes (43.9% male, 56.1% female), with HbA1c more than 9%, on two types of oral diabetic medication or more, were started on basal insulin (glargine, lantus) and followed for three to six months. Overall 82 patients with type 2 diabetes mellitus were included in the study. The mean age of the study population was 58.4 years, the mean duration of the disease range was 13.4 years. All patients with HbA1c more than 9%, without organ failure, were included in the study. The mean HbA1c overall had decreased from mean of 11.15% before starting basal insulin to the mean of 8.43% within 3 to 6 month, after initiating basal insulin, this difference was significant at p < 0.001. There was no adverse effect on this medication in any of the study group. The addition of basal insulin to oral anti-diabetic medication in uncontrolled insulin-na<span style="color:#4F4F4F;font-family:"font-size:14px;white-space:normal;background-color:#F7F7F7;">ï</span>ve type 2 diabetic patients resulted in significant improvement of glycemic control, with improved HbA1c level, without adverse effects.</span> </div>
文摘糖基化血红蛋白（glycosylated hemoglobin）是伊朗科学家Ranbar等应用琼脂糖凝胶电泳分析率先从糖尿病患者血液中发现的一种血红蛋白组分，且研究表明，是血液葡萄糖对HbA的非遗传修饰产生了糖化血红蛋白A1c（haemoglobinA1c,HbA1c）[1,2]。从此，他们与糖尿病的相关性得到确认，这一发现奠定了HbA1c检测用于糖尿病的初筛和诊断的基础。美国糖尿病控制及并发症试验（Diabetes Control and Complications Trial,DCCT）和英国前瞻性糖尿病研究（UK Prospeetive Diabetes Study,UKPDS）历时多年的糖尿病流行病学研究表明糖尿病患者通过治疗，控制平均血糖水平和HbA1c，能够有效地得到治疗，显著降低视网膜病变、肾脏疾病以及神经病变等并发症的发生及其严重程度。
